Phase 4
Completed N=128
Protocolized Initiation of Clonidine to Prevent Dexmedetomidine Withdrawal
Withdrawal; Therapeutic Substance
Source: ClinicalTrials.gov NCT05575219 ↗
Enrolled (actual)
128
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Number of Participants With Withdrawal — 33; 10 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to determine if the protocolized use of clonidine will reduce dexmedetomidine withdrawal symptoms, reduce PICU length of stay, and reduce costs related to sedation during hospital admission.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Withdrawal |
33; 10 | — |
| SECONDARY Hours on Dexmedetomidine |
153.43; 155.33 | — |
| SECONDARY Pediatric Intensive Care Unit (PICU) Length of Stay |
13; 10.5 | — |
| SECONDARY Dexmedetomidine Cost Per Kilogram During Hospitalization |
19.98; 29.46 | — |
| SECONDARY Clonidine Cost Per Kilogram During Hospitalization |
0.06; 0.05 | — |
Eligibility Criteria
Inclusion Criteria
- Dexmedetomidine infusion for greater than or equal to 72 hours
Exclusion Criteria
- Admission for head trauma
- Psychiatric history
- Use of alpha-2 agonist medications at home
- Death while on dexmedetomidine
Data sourced from ClinicalTrials.gov (NCT05575219). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.